Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinxue Liu

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Trials|July 21, 2023
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trialsSarah Kelly, Xinxue Liu, Katherine Theiss-Nyland, et al.
Lancet (London, England)|January 25, 2022
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised studySue Ann Costa Clemens, Lily Weckx, Ralf Clemens, et al.
The Journal of Infection|June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trialEimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
Investigative Radiology|June 26, 2023
Development and Evaluation of Machine Learning in Whole-Body Magnetic Resonance Imaging for Detecting Metastases in Patients With Lung or Colon Cancer: A Diagnostic Test Accuracy StudyAndrea G Rockall, Xingfeng Li, Nicholas Johnson, et al.
Science Immunology|August 29, 2025
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccinesAli Amini, Lucy C Garner, Robert H Shaw, et al.
Nature Genetics|October 15, 2013
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagusDavid M Levine, Weronica E Ek, Rui Zhang, et al.
The Lancet. Infectious Diseases|March 22, 2026
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trialsSanjeev M Bijukchhe, Natalie G Marchevsky, Freddie Kibengo, et al.
Vaccine|May 16, 2026
Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections: a secondary analysis of observational dataNienke N Hagedoorn, Shruti Murthy, Christian S Marchello, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Trials|July 21, 2023
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trialsSarah Kelly, Xinxue Liu, Katherine Theiss-Nyland, et al.
Lancet (London, England)|January 25, 2022
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised studySue Ann Costa Clemens, Lily Weckx, Ralf Clemens, et al.
The Journal of Infection|June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trialEimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
Investigative Radiology|June 26, 2023
Development and Evaluation of Machine Learning in Whole-Body Magnetic Resonance Imaging for Detecting Metastases in Patients With Lung or Colon Cancer: A Diagnostic Test Accuracy StudyAndrea G Rockall, Xingfeng Li, Nicholas Johnson, et al.
Science Immunology|August 29, 2025
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccinesAli Amini, Lucy C Garner, Robert H Shaw, et al.
Nature Genetics|October 15, 2013
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagusDavid M Levine, Weronica E Ek, Rui Zhang, et al.
The Lancet. Infectious Diseases|March 22, 2026
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trialsSanjeev M Bijukchhe, Natalie G Marchevsky, Freddie Kibengo, et al.
Vaccine|May 16, 2026
Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections: a secondary analysis of observational dataNienke N Hagedoorn, Shruti Murthy, Christian S Marchello, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
Pageof 10